关于与专业投资机构共同投资的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 一、投资的基本情况 天津九安医疗电子股份有限公司（以下简称"公司"）全资子公司 Andon Ho ng Kong Co., Limited（以下简称"九安香港"）以有限合伙人身份使用自有资金 人民币 31,298.85 万元人民币或等值美元，与北京尚势投资管理有限公司（以下 简称"尚势投资"）共同设立天津市九尚创业投资合伙企业（有限合伙）（以下简 称"九尚创投"）。九尚创投及尚势投资共同设立天津九尚一号管理咨询合伙企业 （有限合伙）（以下简称"九尚一号"）。本次投资的目的是以九尚一号为主体向 境内创业投资型基金、初创企业等进行投资。具体内容详见公司于 2023 年 12 月 29 日披露的《关于与专业投资机构共同投资的公告》（公告编号：2023-077）。 二、投资的进展情况 证券代码：002432 证券简称：九安医疗 公告编号：2025-086 天津九安医疗电子股份有限公司 九安香港于近日收到管理人（暨普通合伙人）尚势投资的通知，九尚创投已 募集完成，截至目前已收到全体合伙 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-083 天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2025年10月 22日以通讯方式发出召开第六届董事会第二十八次会议的通知，会议于2025年10 月24日在公司会议室以现场和通讯表决相结合方式召开。本次会议由公司董事长 刘毅先生主持，会议应参加的董事6名，实际参加的董事6名，全体监事、公司高 级管理人员列席了会议，符合《公司法》及《公司章程》的规定。根据《公司章 程》规定，与会董事就会议议案进行了审议、表决并通过了如下议案： 天津九安医疗电子股份有限公司 第六届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 具 体 内 容 详 见 公 司 同 日 刊 登 于 《 证 券 时 报 》 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）的《关于与专业投资机构共同投资的公告》（公告 编号：2025-085）。 特此公告。 天津九安医疗电子股份有限公司董事会 2025 年 10 月 25 日 一、以6票同意、0票反对、0票弃权的 ...

Core Viewpoint - Ji'an Medical reported a significant decline in revenue and net profit for the third quarter, indicating potential challenges in the company's financial performance [1] Financial Performance - The company's revenue for the third quarter was 304 million yuan, a year-on-year decrease of 58.98% [1] - Net profit for the third quarter was 669 million yuan, down 12.78% year-on-year [1] - For the first three quarters, total revenue was 1.069 billion yuan, reflecting a year-on-year decline of 48.89% [1] - Net profit for the first three quarters was 1.589 billion yuan, which represents a year-on-year increase of 16.11% [1]

Core Insights - On October 23, Jiuan Medical's stock rose by 0.75%, with a trading volume of 257 million yuan, indicating positive market sentiment towards the company [1] - The company reported a significant decrease in revenue for the first half of 2025, with a 43.35% year-on-year decline, while net profit increased by 52.91% [2] Financing and Trading Activity - On October 23, Jiuan Medical had a financing buy-in amount of 68.42 million yuan, with a net financing buy of 30.20 million yuan, indicating strong investor interest [1] - The total financing and securities lending balance reached 1.22 billion yuan, with financing balance accounting for 6.47% of the circulating market value, which is above the 80th percentile of the past year [1] - The securities lending balance was 9.86 million yuan, with a lending volume of 244,100 shares, also above the 90th percentile of the past year [1] Shareholder and Institutional Holdings - As of October 20, the number of Jiuan Medical shareholders decreased to 69,800, while the average circulating shares per person increased by 3.30% to 6,651 shares [2] - The company has distributed a total of 1.794 billion yuan in dividends since its A-share listing, with 1.39 billion yuan distributed in the last three years [3] - Notable institutional holdings include Huabao Zhongzheng Medical ETF and Southern Zhongzheng 500 ETF, with both reducing their holdings [3]

Group 1 - The core viewpoint of the article is that Ji'an Medical (002432) is actively engaging in share repurchase to maintain its market value and protect shareholder interests [1] - The company has completed the cancellation of 29,954,222 shares of treasury stock as part of its ongoing efforts to enhance market value [1] - A new share repurchase plan has been initiated, with a total funding amount between 300 million RMB and 600 million RMB, to be executed within three months from the board's approval [1] Group 2 - The repurchased shares will be used to maintain company value and shareholder rights, and can be sold through centralized bidding after a 12-month disclosure period [1] - Any unsold shares after three years will be legally canceled, ensuring that the company adheres to regulatory requirements [1]

出席本次说明会的人员有：公司董事长兼总经理刘毅先生，董事兼副总经理 王湧先生，董事兼副总经理丛明先生，独立董事孙卫军先生，董事会秘书邬彤先 生，财务经理秦菲女士（代行财务总监职责）。 为充分尊重投资者、提升交流质量，现就公司 2025 年第三季度网上业绩说 明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2025 年 10 月 27 日（星期一）12:00 前将所需了解的情况和问题一并发送至邮箱 ir@jiuan.com。 证券代码：002432 证券简称：九安医疗 公告编号：2025-082 天津九安医疗电子股份有限公司 关于举办2025年第三季度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）《2025 年第三季度报告》 将于 2025 年 10 月 25 日披露于巨潮资讯网（www.cninfo.com.cn），为了让广大投 资者能进一步了解公司 2025 年前三季度的经营和财务情况，公司将于 2025 年 10 月 27 日下午 15:00-16:00 在东方财 ...

Group 1 - The company, Ji'an Medical, holds approximately 0.05% of shares in Zhiyuan Innovation (Shanghai) Technology Co., Ltd. through its investment in the Qiji Chuangtan Phase II Fund as of the end of the first half of 2025 [2]

Core Viewpoint - Jiuan Medical (002432.SZ) has announced its indirect ownership of approximately 0.05% of Zhiyuan Innovation (Shanghai) Technology Co., Ltd. through its investment in the Qiji Chuangtan Phase II Fund, as of the end of the first half of 2025 [1] Group 1 - Jiuan Medical is participating in the Qiji Chuangtan Phase II Fund [1] - The investment allows Jiuan Medical to hold a minor stake in Zhiyuan Innovation [1] - The indirect ownership percentage is approximately 0.05% [1]

格隆汇10月22日丨九安医疗(002432.SZ)在投资者互动平台表示，截至2025年半年末，公司通过参投奇 绩创坛二期基金，间接持有智元创新（上海）科技有限公司约0.05%的股份。 ...

Core Viewpoint - After the decline of dividends, the company is shifting its focus towards investment opportunities, initiating a second share buyback plan in 2025 to maintain company value and protect shareholder rights [2][3]. Group 1: Share Buyback and Stock Performance - The company announced a share buyback plan on October 14, 2025, intending to use 300 million to 600 million yuan of its own funds and special loans [2]. - Despite the buyback, the company's stock price has decreased over 7% since the last buyback announcement, while the broader market has increased by over 20% during the same period [2]. - The company's stock price has fallen below its latest net asset value per share, prompting the buyback to protect shareholder interests [2]. Group 2: Financial Performance and Investment Strategy - The company experienced a significant increase in net profit, reaching 9.2 billion yuan in the first half of 2025, a year-on-year growth of over 50%, despite a decline in revenue from its core internet medical products and services [5]. - The unusual situation of declining revenue but rising profits is attributed to substantial investment income, with fair value changes contributing 734 million yuan, ten times the previous year's figure [5]. - The company has engaged in various investments, including venture capital funds, with a total estimated investment of approximately 4.363 billion yuan since September 2022 [6]. Group 3: Historical Context and Growth - The company’s growth trajectory began during the COVID-19 pandemic, achieving significant sales increases due to timely inventory management and product demand [4]. - In 2022, the company reported a revenue of 26.315 billion yuan, a staggering increase of 997.8% year-on-year, driven by large orders for COVID-19 testing kits [4]. - The company has received over 2.4 billion USD in orders from U.S. federal and state governments from December 2021 to 2023, marking a significant achievement in the IVD sector [4]. Group 4: Investment Expansion - The company has made strategic investments in various sectors, including hard technology, healthcare, artificial intelligence, and new materials, aiming for long-term returns [6][8]. - Recent investments include acquiring a 20% stake in iHealth from Xiaomi for approximately 459.1 million USD, increasing its ownership to 100% [8]. - The company is also exploring opportunities in the electric vehicle sector, holding shares in several automotive companies, including Tesla and NIO [9].